Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
Transferred WT1-Reactive CD8 + T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
2013
Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
2016
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
2010
Immunological aspects of cancer chemotherapy
2007
Smarter drugs emerging in pancreatic cancer therapy
2014
Differential Membrane Localization of ERas and Rheb, Two Ras-related Proteins Involved in the Phosphatidylinositol 3-Kinase/mTOR Pathway
2005 StandoutNobel
mRNA expression of leukemia‐associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies
2003
Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
2011
Testicular Germ-Cell Cancer
1997 Standout
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease
2002
Chronic Myeloproliferative Disorders
2003
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma
2009
Monitoring response to therapy in cancer using [ 18 F]-2-fluoro-2-deoxy- d -glucose and positron emission tomography: an overview of different analytical methods
2000
Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL)
2001
Physical Principles of Membrane Shape Regulation by the Glycocalyx
2019 StandoutNobel
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
2007 Standout
Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease
1991
Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
1997
Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease
2004
Infections in adults undergoing unrelated donor bone marrow transplantation
1999
Anaplastic lymphoma kinase proteins in growth control and cancer
2004
Shared Principles in NF-κB Signaling
2008 Standout
Immunotherapy of Hematologic Malignancy
2003
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma
2004
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
1999 Standout
The role of positron emission tomography (PET) in the management of lymphoma patients
1999
Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy
2016
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
2011
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
2010
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Pancreatic Adenocarcinoma
2014 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
The PI3K pathway in B cell metabolism
2016
Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation
2009 Standout
FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease
2006
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Immunity, Inflammation, and Cancer
2010 Standout
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
2010 Standout
Translocations involving anaplastic lymphoma kinase (ALK)
2001
Aspergillosis Case-Fatality Rate: Systematic Review of the Literature
2001 Standout
Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol.
1991
Infectious and immunosuppressive complications of purine analog therapy.
1995
Hematopoietic Stem-Cell Transplantation
2006 Standout
Ras and relatives—job sharing and networking keep an old family together
2002
Cancer immunotherapy comes of age
2011 StandoutNature
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
2003
Sarcoidosis
1997 Standout
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation
2004
Revealing the world of RNA interference
2004 StandoutNatureNobel
Interleukin-2: Clinical applications
2002
18p-FDG PET is superior to67Ga SPECT in the staging of non-Hodgkin’s lymphoma
2004
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
2000 StandoutNature
let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells
2007 Standout
A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies
1999
Hepatitis C, Hepatitis B, and Human Immunodeficiency Virus Infections among Non-Intravenous Drug-Using Patients Attending Clinics for Sexually Transmitted Diseases
1994
The PI3K Pathway in Human Disease
2017 Standout
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Cancer-related inflammation
2008 StandoutNature
Expression of the Bcl-3 proto-oncogene suppresses p53 activation
2005
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
2007 Standout
Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
2002 StandoutNobel
Sorafenib for the Treatment of Advanced Renal Cell Carcinoma
2006
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
2002 StandoutScience
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
Transcription Factors, Normal Myeloid Development, and Leukemia
1997
Acute Myeloid Leukemia
2015 Standout
Phenotypic characterization of human colorectal cancer stem cells
2007 Standout
Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies
2003
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma
1999 StandoutNobel
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Randomized Phase II/III Trial of Interferon Alfa-2a With and Without 13-cis-Retinoic Acid in Patients With Progressive Metastatic Renal Cell Carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951)
2005
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
Group IB Secretory Phospholipase A2 Stimulates CXC Chemokine Ligand 8 Production via ERK and NF-κB in Human Neutrophils
2004
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
2009 Standout
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants
2003
Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
2001
Chronic lymphocytic leukemia of Eμ-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression
2009
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Cancer Stem Cells: Models and Concepts
2006
Cytokine Storm
2020 Standout
Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma
2002
Antibody therapy for acute myeloid leukaemia
2013
Bcl-2 Cooperates with Promyelocytic Leukemia Retinoic Acid Receptor α Chimeric Protein (Pmlrarα) to Block Neutrophil Differentiation and Initiate Acute Leukemia
2001 Nobel
How I treat refractory and early relapsed acute myeloid leukemia
2015
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma
2007
Carcinoma Cell Hyaluronan as a “Portable” Cancerized Prometastatic Microenvironment
2016
Molecular mechanisms of resistance of leukemia to imatinib mesylate
2003
Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose
2007
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Multiple Myeloma
2011 Standout
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma
2001
Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.
2006
Transcription Factors, Normal Myeloid Development, and Leukemia
1997
Works of Lothar Bergmann being referenced
Positron Emission Tomography (PET) for Staging of Solitary Plasmacytoma
2003
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers
2012
Wilms Tumor Gene Expression in Acute Myeloid Leukemias
1997
CD30-mediated cell cycle arrest associated with induced expression of p21CIP1/WAF1 in the anaplastic large cell lymphoma cell line Karpas 299
2001
The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation
1999
High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia
1998
Establishment and characterization of a new, factor-independent acute myeloid leukemia line designated Ei501
1997
Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia
1993
9 Fertility, pregnancy and the management of myeloproliferative disorders
1998
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
2004
The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR
1995
Non-infectious lung complications are closely associated with chronic graft-versus-host disease: a single center study of incidence, risk factors and outcome
2000
Real‐time RT‐PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)‐positive AML patients
1999
Risk-adapted induction and consolidation therapy in adults with de novo AML aged =�60�years: results of a prospective multicenter trial
2004
Rapid Cytokine Release in Cancer Patients Treated with Interleukin-2
1992
Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials
1993
Curcumin Inhibits Constitutive STAT3 Phosphorylation in Human Pancreatic Cancer Cell lines and Downregulation of Survivin/BIRC5 Gene Expression
2009
Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies
1996
Progress in medical imaging of lymphoma and Hodgkin’s disease
1999
Interleukin-2 Bolus Infusion as Late Consolidation Therapy in 2nd Remission of Acute Myeloblastic Leukemia
1995
Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease
1998
Receptor for hyaluronan acid–mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia
2002
Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
2013
Wilms Tumor Gene (wt1) mRNA Is Equally Expressed in Blast Cells From Acute Myeloid Leukemia and Normal CD34+ Progenitors
1997
Disseminated testicular cancer with bulky disease: results of a phase‐II study with cisplatin ultra high dose/VP‐16/bleomycin
1987
Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?
2000
Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?
2000
Lymphocyte transformation test in a group of foundry workers exposed to beryllium and non-exposed controls.
1986
Simultaneous expression of different immunogenic antigens in acute myeloid leukemia
2000
High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome
1997
Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-κB/Rel–regulated inhibitors of apoptosis
2002
The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells.
1994
Rhenium 188–labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study
2001
Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
2004